In some countries, this medicine may only be approved for veterinary use.
In the US, Olsalazine (olsalazine systemic) is a member of the drug class 5-aminosalicylates and is used to treat Ankylosing Spondylitis, Ulcerative Colitis, Ulcerative Colitis - Active and Ulcerative Colitis - Maintenance.
US matches:
- Olsalazine
- Olsalazine Sodium
Scheme
Rec.INN
ATC (Anatomical Therapeutic Chemical Classification)
A07EC03
CAS registry number (Chemical Abstracts Service)
0015722-48-2
Chemical Formula
C14-H10-N2-O6
Molecular Weight
302
Therapeutic Category
Gastrointestinal agent
Chemical Name
Benzoic acid, 3,3'-azobis[6-hydroxy-
Foreign Names
- Olsalazinum (Latin)
- Olsalazin (German)
- Olsalazine (French)
- Olsalazina (Spanish)
Generic Names
- Olsalazine (OS: DCF, BAN)
- C.I. Mordant Yellow 5 (IS: WHO)
- Olsalazine Sodium (OS: BANM, USAN)
- ADS (IS)
- Azodisal sodium (IS)
- CI 14130 (IS)
- Disodium azobis (IS)
- DSA (IS)
- Olsalazine sodique (PH: Ph. Eur. 6)
- Olsalazine Sodium (PH: BP 2010, Ph. Eur. 6)
- Olsalazin-Natrium (PH: Ph. Eur. 6)
- Olsalazinum natricum (PH: Ph. Eur. 6)
Brand Names
- Dipentum
Pharmabroker, New Zealand; Celltech, Iceland; Celltech, United States; Pfizer, Chile; Pfizer, Israel; Pfizer, Oman; UCB, Austria; UCB, Australia; UCB, Canada; UCB, Germany; UCB, Denmark; UCB, Finland; UCB, France; UCB, Hong Kong; UCB, Ireland; UCB, Latvia; UCB, Netherlands; UCB, Norway; UCB, Sweden; UCB, United States; UCB, South Africa; UCB Pharma, United Kingdom; UCB-Pharma, Switzerland - Dipentum (veterinary use)
UCB, United Kingdom
International Drug Name Search
Glossary
BAN | British Approved Name |
BANM | British Approved Name (Modified) |
DCF | Dénomination Commune Française |
IS | Inofficial Synonym |
OS | Official Synonym |
PH | Pharmacopoeia Name |
Rec.INN | Recommended International Nonproprietary Name (World Health Organization) |
USAN | United States Adopted Name |
WHO | World Health Organization |
Click for further information on drug naming conventions and International Nonproprietary Names.
No comments:
Post a Comment